To Get Help Now
Click Here
 
Today's Date:

Settlement Could Be Close In Whistleblower Lawsuit Against Abbott’s Depakote Off-Label Marketing

AddThis Social Bookmark Button

The U.S. Department of Justice has intervened in several whistleblower lawsuits filed on behalf of Thomas Spetter Jr. and three other groups regarding the off-label marketing of Depakote, an epilepsy drug, and whether the pharmaceutical company violated civil and criminal laws, including defrauding Medicare and Medicaid.

Spetter said in court filings that he received conflicting training as a pharmaceutical sales representative in the 1990s. He said that at first, he was told to market drugs only for purposes approved by the FDA. However, he said that he and other trainees were told behind closed doors, to market Depakote as also a treatment for the agitation that goes with dementia.

The lawsuits allege that not only did Abbott train sales reps to market Depakote for off-label uses but that the company also gave doctors illegal kickbacks for spreading the word about off-label uses.

The Chicago Tribune reported that last month Abbott announced it set aside $1.5 billion for Depakote settlement discussions.

Depakote was approved in 1983 as a treatment for some types of seizures in individuals over the age of ten. Since then, it has been approved to treat manic episodes of bipolar disorder, to prevent migraine headaches, and for some other types of seizures.

 

 

breakinglawsuitnews.com disclaimer: This article: Settlement Could Be Close In Whistleblower Lawsuit Against Abbott’s Depakote Off-Label Marketing was posted on Monday, November 14th, 2011 at 9:46 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.